EditorialEditorial
If You Want to Perform a Cost-effectiveness Trial, First Do a Modeling Study
Wietske Kievit and Alfons A. den Broeder
The Journal of Rheumatology April 2021, 48 (4) 473-475; DOI: https://doi.org/10.3899/jrheum.201430
Wietske Kievit
1W. Kievit, PhD, Assistant Professor in Health Technology Assessment, Radboud University Medical Centre, Radboud Institute for Health Science, Department for Health Evidence, Nijmegen;
Alfons A. den Broeder
2A.A. den Broeder, MD, PhD, Rheumatologist and Epidemiologist, Department of Rheumatology, Sint Maartenskliniek, Nijmegen, the Netherlands.
REFERENCES
- 1.↵
- Verhoeven MM,
- Tekstra J,
- van Laar JM,
- Petho-Schramm A,
- Borm ME,
- Bijlsma JW, et al.
- 2.↵
- Bijlsma JW,
- Welsing PM,
- Woodworth TG,
- Middelink LM,
- Pethö-Schramm A,
- Bernasconi C, et al.
- 3.↵
- Smolen JS,
- Landewé RB,
- Bijlsma JW,
- Burmester GR,
- Dougados M,
- Kerschbaumer A, et al.
- 4.↵
- Hetland ML,
- Haavardsholm EA,
- Rudin A,
- Nordstrom D,
- Nurmohamed M,
- Gudbjornsson B, et al.
- 5.↵
- 6.↵
In this issue
The Journal of Rheumatology
Vol. 48, Issue 4
1 Apr 2021
If You Want to Perform a Cost-effectiveness Trial, First Do a Modeling Study
Wietske Kievit, Alfons A. den Broeder
The Journal of Rheumatology Apr 2021, 48 (4) 473-475; DOI: 10.3899/jrheum.201430